Start Date

22-5-2012 4:30 PM

End Date

22-5-2012 6:00 PM

Description

Introduction: Novel methods of identifying individuals at risk for atrial fibrillation (AF) are needed. MicroRNAs (MiRNAs) regulate gene expression in a number of cardiovascular diseases, including AF. It is unknown, however, if key circulating, cardiac-specific miRNAs differ between individuals with paroxysmal or persistent AF and those in sinus rhythm.

Methods: 17 individuals with a history of AF were recruited prior to catheter ablation. 24 hospitalized patients in normal sinus rhythm and no history of AF comprised the control group. 94 plasma miRNAs were selected based on a priori associations with processes implicated in AF for evaluation using the TaqMan miRNA expression profiling system.

Results: We found that miRNA expression differed by at least 2-fold for 14 miRNAs, including several previously implicated in cardiovascular remodeling and disease (Figure 1). Levels of miR-7, miR-208, and miR-302b were statistically significantly up- or down-regulated in AF patients relative to controls (p<0.05) and levels of miR-218 differed by greater than 20-fold (p=0.095).

Application: Although power was limited by the modest sample size, these data support the rationale for using circulating miRNA as AF biomarkers. Moreover, since miRNA can modulate disease pathways, miRNA-based therapeutics would theoretically enable targeting of novel gene regulatory pathways implicated in AF in a unique and powerful manner.

Next Steps/ Future: Further investigations involving well-characterized, large samples from longitudinal studies with standardized miRNA assessment and evaluation for AF are required to validate the observed associations.

Creative Commons License


This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

 
May 22nd, 4:30 PM May 22nd, 6:00 PM

Circulating microRNAs are associated with Paroxysmal or Persistent Atrial Fibrillation

Introduction: Novel methods of identifying individuals at risk for atrial fibrillation (AF) are needed. MicroRNAs (MiRNAs) regulate gene expression in a number of cardiovascular diseases, including AF. It is unknown, however, if key circulating, cardiac-specific miRNAs differ between individuals with paroxysmal or persistent AF and those in sinus rhythm.

Methods: 17 individuals with a history of AF were recruited prior to catheter ablation. 24 hospitalized patients in normal sinus rhythm and no history of AF comprised the control group. 94 plasma miRNAs were selected based on a priori associations with processes implicated in AF for evaluation using the TaqMan miRNA expression profiling system.

Results: We found that miRNA expression differed by at least 2-fold for 14 miRNAs, including several previously implicated in cardiovascular remodeling and disease (Figure 1). Levels of miR-7, miR-208, and miR-302b were statistically significantly up- or down-regulated in AF patients relative to controls (p<0.05) and levels of miR-218 differed by greater than 20-fold (p=0.095).

Application: Although power was limited by the modest sample size, these data support the rationale for using circulating miRNA as AF biomarkers. Moreover, since miRNA can modulate disease pathways, miRNA-based therapeutics would theoretically enable targeting of novel gene regulatory pathways implicated in AF in a unique and powerful manner.

Next Steps/ Future: Further investigations involving well-characterized, large samples from longitudinal studies with standardized miRNA assessment and evaluation for AF are required to validate the observed associations.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.